Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation | Annals of Surgical Oncology
Table 1 from Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube
Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Tumor Marker CA 19-9 for Assessing Pancreatic Cancer Response - Cancer Therapy Advisor
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
Tumor Marker Control | Fujirebio
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Old Dog, New Tricks: Use of CA 19-9 for Early Diagnosis of Pancreatic Cancer - Gastroenterology
Comparison of two immunoassays for CA19-9, CEA and AFP tumor markers - Biochemia Medica
Post-Resection CA 19-9 Predicts Overall Survival in Patients Treated with Adjuvant Chemoradiation; RTOG 9704 A. Berger, K. Winter, J. Hoffman, W. Regine, - ppt download
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect
Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers
IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite
CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma | PLOS ONE
CA19-9 for detecting recurrence of pancreatic cancer | Scientific Reports
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
CA 19.9 - Pancreatic Cancer Marker – Beacon Health Screening Centre
Positivities ofcombined tumour marker tests in patients with diseases... | Download Table
CA-19-9 - Diagnostic Kit
Tumor markers in clinical practice Colorectal - CEA Hepatocellular ... | GrepMed
